| Identification | Back Directory | [Name]
D-Phenylalanine, N-[6-[4-(phenylmethoxy)phenyl]-4-pyrimidinyl]- | [CAS]
693790-96-4 | [Synonyms]
BAY 73-1449
D-Phenylalanine, N-[6-[4-(phenylmethoxy)phenyl]-4-pyrimidinyl]- | [Molecular Formula]
C26H23N3O3 | [MDL Number]
MFCD32899871 | [MOL File]
693790-96-4.mol | [Molecular Weight]
425.48 |
| Chemical Properties | Back Directory | [Boiling point ]
700.4±60.0 °C(Predicted) | [density ]
1.273±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 250 mg/mL (587.57 mM) | [form ]
Solid | [pka]
3.35±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
BAY 73-1449 is a selective antagonist of prostacyclin receptor (IP), with high potency (IC50 of less than 0.1 nM) in cAMP assays in Human HEL cells and rat DRG. BAY 73-1449 can be used in the research of lowering blood pressure[1]. | [in vivo]
BAY 73-1449 (0.1-1 mg/kg; i.v.) does not significantly reduce mesenteric inflow, but significantly reduces splenic shunt vessel outflow in rats[1].
BAY 73-1449 (1-5 mg/kg, s.c. once daily for 7 d) has no effects on the degree of porto-systemic shunting in rats[1].
BAY 73-1449 (1 mg/kg, s.c. once daily for 7 d), has no effects on portal pressures in rats[1]. | Animal Model: | Male Wistar rats (250-350 g) are ligated portal vein[1] | | Dosage: | 0.1, 1 mg/kg | | Administration: | A single i.v. | | Result: | Significantly reduced shunt flow without affecting mesenteric flow. |
| [IC 50]
IP Receptor: <0.1 nM (IC50) | [References]
[1] Bexis S, et, al. Vascular actions of the prostacyclin receptor antagonist BAY 73-1449 in the portal hypertensive rat. Eur J Pharmacol. 2008 Aug 20;590(1-3):322-6. DOI:10.1016/j.ejphar.2008.06.006 |
|
|